[324 Pages Report] Globally, more than 1 billion individuals are overweight or obese and the numbers continue rising. This high prevalence of obesity will drive demand for obesity management products and services in the long term.

According to the World Health Organization (WHO), approximately 1.9 billion adults were overweight and 650 million adults were obese. Whereas 38.3 million children under 5 years of age were either overweight or obese in 2019. One in three adults in North America is obese. In the U.S., 80 million adults and 12.7 million children suffer from obesity.

Obesity is a prominent community health problem in many parts of the world. It is associated with numerous health disorders including gallbladder disease, heart disease, diabetes, stroke, hypertension, and fatty liver disease in addition to some cancers. According to a recent Future Market Insights (FMI) report, the market is set to surpass US$ 1.2 Bn by the end of the forecast period in 2031, with a CAGR of over 5%.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-587

Furthermore, there has been an increase in the per capita healthcare expenditure, especially in developed countries, with better reimbursement policies. People are now inclined towards out-of-pocket expenditure healthcare. Personal health, grooming, and concerns over social discrimination are leading people to take obesity management consultations.

However, the unprecedented pandemic crisis has had a significant impact on the obesity management market due to a slump of patient footfall in hospitals and clinics. Preference is now being given to the treatment of COVID-19 patients, limiting resources for anti-obesity consultations and related drugs or surgeries.

Also, there has been a halt in clinical trials for weight management drugs. However, with the availability and commencement of the COVID-19 vaccination, the clinical trials are resuming and are anticipated to pick up pace during the forecast period. Also, the adoption of telehealth and in developing countries is likely to bode well for the future of the market in the long term.

Key Takeaways from Obesity Management Market Study

• Bupropion and Naltrexone will reflect register faster growth at a CAGR of 8.4%, owing to an increase in the preference for combination therapy in weight management.
• Gastric sleeve surgery will account for over 40% of the market throughout the forecast period owing to benefits of simplicity and time-efficiency.
• The U.S. will lead the North America market with a share of over 64% in 2021, driven by continuing diet and lifestyle issues prevalent in the country.
• Germany followed by Russia are leading markets in Europe, reflecting CAGR of over 6% through the end of 2031, driven by improvements in public health programs.
• Japan dominates the East Asia market, accounting for 49% value share in 2021, with government awareness programs contributing to growth.

Ask from Market Research Expert - https://www.futuremarketinsights.com/ask-question/rep-gb-587

"The rapidly increasing obesity cases and the resultant chronic diseases have triggered concern among patients and healthcare professionals. The COVI-19 crisis has alarmed people, as overweight people are at higher risk of acquiring SARS-COV2. This consciousness may help in encouraging obesity management uptake through 2021 and beyond," says the FMI analyst.

Key Participant Insights

Prominent players in the Obesity Management Market are focusing on collaborations, mergers & acquisitions for global expansion and enhanced opportunities focused on emerging economies thereby, enhancing their market presence.

The key market players covered by FMI include GlaxoSmithKline Plc., VIVUS, Inc., Novo Nordisk A/S, Currax Pharmaceuticals LLC, Cheplapharm Arzneimittel GmbH, Bausch Health Companies Inc., and Takeda Pharmaceuticals, Inc.

Obesity Management Market by Category

By Drug Type:

• Bupropion and Naltrexone
• Orlistat
• Lorcaserin
• Phentermine and Topiramate
• Liraglutide

For in-depth insights, Download a PDF Brochure - https://www.futuremarketinsights.com/reports/brochure/rep-gb-587

By Surgery Type:

• Gastric Bypass Surgery
• Adjustable Gastric Banding Surgery
• Gastric Sleeve Surgery
• Duodenal Switch Surgery
• Others

By Distribution Channel:

• Hospitals Pharmacies
• Retail Pharmacies
• E-commerce

More Trending Reports by Future Market Research :

Meningitis Treatment Market : The meningitis treatment market is set to fuel at a CAGR of 4.1% between 2022 and 2032. The market is expected to hold a value of US$ 146.6 Million in 2022 and is anticipated to cross a valuation of US$ 219.10 Million by 2032.

Bionic Eye Market : The bionic eye market is set to flourish at a CAGR of 12.5% between 2023 and 2033. The market is expected to reach a value of US$ 297.14 Million in 2023 while it is anticipated to achieve a valuation of US$ 964.91 Million by 2033.

Hypogonadism Treatment Market : The global hypogonadism treatment market is estimated to register a CAGR of 5% during the forecast period, during the forecast period and registers a revenue valued at US$ 3.62 Bn in 2022, and is expected to cross US$ 5.90 Bn by 2032.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights,

Unit No: 1602-006,

Jumeirah Bay 2,

Plot No: JLT-PH2-X2A,

Jumeirah Lakes Towers,

Dubai,

United Arab Emirates

For Sales Enquiries: [email protected]

Website: https://www.futuremarketinsights.com

LinkedIn| Twitter| Blogs

The post Obesity Management Market is expected to grow with a CAGR of 5.1%, from USD 828.71 million in 2022 to USD 1362.80 million by 2032 | FMI appeared first on Future Market Insights.

Original Source of the original story >> Obesity Management Market is expected to grow with a CAGR of 5.1%, from USD 828.71 million in 2022 to USD 1362.80 million by 2032 | FMI

This content is published on behalf of the above source. Please contact them directly for any concern related to the above.

This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.